Allogeneic Stem Cell Transplantation in Myelofibrosis

This review describes the recent data on various peri-transplantation factors and their effect on outcomes of patients with myelofibrosis, as well as new therapeutic areas, such as the use and timing of Janus kinase inhibitors with allogeneic stem cell transplantation, and gives overall conclusions from the available data in the published literature.

 Biol Blood Marrow Transplant

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.